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Abstract: Chronic obstructive pulmonary disease (COPD) and lung cancer result in 
significant morbidity and mortality worldwide. In addition to the role of environmental 
smoke exposure in the development of both diseases, recent epidemiological studies 
suggests a connection between the development of COPD and lung cancer. Furthermore, 
individuals with concomitant COPD and cancer have a poor prognosis when compared 
with individuals with lung cancer alone. The modulation of molecular pathways activated 
during emphysema likely lead to an increased susceptibility to lung tumor growth and 
metastasis. This review summarizes what is known in the literature examining the 
molecular pathways affecting matrix metalloproteinases (MMPs) in this process as well as 
external factors such as smoke exposure that have an impact on tumor growth and 
metastasis. Increased expression of MMPs provides a unifying link between lung cancer 
and COPD. 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) and lung cancer are both significant causes of 
morbidity and mortality in the United States and worldwide. It is estimated that approximately  
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400,000 deaths occur each year due to COPD [1], and there is a 15.0% 5-year survival rate for late 
stage lung cancer patients, a point of time when 85% of lung cancer is diagnosed [2]. Recent studies 
have shown that both COPD and lung cancer share a similar genetic pre-disposition [3]. It is well 
understood that patients diagnosed with COPD have a higher risk of lung cancer [4], and the presence 
of computed-tomography diagnosed emphysema is linked to a lower survival rate among patients with 
early onset lung cancer [5]. The incidence of COPD increases the risk of lung cancer up to 4.5 fold, 
with the onset of lung cancer associated with a greater severity of COPD [3,6]. This poor prognosis for 
lung cancer is associated with reduced lung function seen in patients with COPD. Emphysema is the 
result of lung destruction and is a component of the complex phenotype of COPD. The diagnosis of 
emphysema is characterized pathologically [5,7] with the forced expiratory volume in 1 second (FEV1) 
serving as a proxy for a patient’s lung damage. Epidemiological evidence has demonstrated that a low 
FEV1 is associated with an increased risk of lung cancer in middle aged white males [8]. These interesting 
associations suggest that COPD and lung cancer potentially have overlapping pathological processes. 
Cigarette smoke is the major common etiologic agent that activates mechanisms leading to the 
development of COPD and lung cancer [9]. Cigarette smoke constituents induce inflammation and 
oxidative stress in lung tissue [10,11], which alters the transcription and activation of proteases 
generating an imbalance of proteolytic enzymes and their inhibitors [12] within the parenchyma of the 
lung. The imbalance between proteinases and their inhibitors, defined as the proteinase-anti-proteinase 
theory, in addition to genetic modulation, causes damage to the lung tissue [11] and could predispose 
to lung cancer progression. 
Matrix metalloproteinases (MMPs) are the major proteinases responsible for the digestion and 
degradation of structural proteins of the lung [13]. Fibrillar collagen is a critical extracellular matrix 
(ECM) molecule, produced by various stromal cells, that provide the material necessary for the cellular 
organization of the lung, and comprises 60% of lung protein [14]. Collagenases (MMP-1, MMP-8 and 
MMP-13) can digest major fibrillar collagens at the triple-helical domain [15]. The digestion of the 
collagen fibril is an essential step in the remodeling of tissue architecture in vivo. MMP-8 is the major 
collagenase produced in neutrophils and plays important roles in the acute phase of the inflammatory 
process, while MMP-1 and MMP-13 are thought to be vital in physiological tissue remodeling and 
chronic tissue remodeling under various pathological conditions [15]. 
The expression of MMPs is tightly regulated at the transcriptional level by extracellular stimuli, 
hormones, growth factors, cytokines, cell-cell and cell-ECM interactions and transformation [16]. Our 
laboratory has demonstrated that lung parenchymal cells in patients with emphysema express MMP-1, 
as opposed to smokers without the disease [17], and through in vitro and in vivo studies, we 
demonstrated that cigarette smoke can directly induce MMP production in epithelial cells in a MAP 
Kinase dependent fashion [18]. Subsequent studies identified a novel cigarette smoke responsive 
(CSR) element within the promoter region of MMP-1 [19]. We further delineated the upstream 
signaling pathway regulating MMP-1 induction by cigarette smoke and identified Toll-Like Receptor 4 
(TLR4) as an important regulator of the induction of MMP-1 [20]. TLR4s are classically involved in 
innate and adaptive immunity through their recognition of pathogen associated molecular patterns [21]. 
Recently, studies have shown that TLR4s are activated by cigarette smoke in mice and rabbits, and 
have a role in the regulation MMP-1 production, oxidative stress, and autophagy in lung cells, [20,22]. 
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It is our hypothesis that the modulation of molecular pathways that are activated during emphysema 
and lead to protease production predispose the lung to tumor growth and metastasis. The present 
review presents in vitro and in vivo studies exploring the modulation of biological pathways that 
influence activation and up regulation of MMPs, promote tumor growth, metastasis, and increase the 
likelihood of developing COPD and emphysema in both mice and humans (Figure 1). 
 
Figure 1. High MMPs microenvironment to promote and sustain emphysema and cancer progression. 
2. Lung Diseases and Collagenases 
2.1. COPD and Collagenases 
MMP-1, MMP-8, and MMP-13, are members of the MMP sub family of collagenases, and each has 
been implicated in the development of COPD in response to cigarette smoke both in vitro and in vivo. 
As described above, our laboratory has demonstrated a major role for MMP-1 in the development of 
emphysema [17,19,23–25]. Genetic studies have also supported the increase in MMP-1 observed, as  
in vitro studies have shown an increase in MMP-1 promoter activity in the presence of 5% cigarette 
smoke extract (CSE) [19,25]. 
Early animal studies directly demonstrated that increased local expression of MMP-1 promotes 
emphysema and lung degradation in transgenic mice expressing the human MMP-1 gene [23] within 
lung parenchymal cells. Further, when MMP-1 was expressed in the epidermis of transgenic mice, 
hyperproliferation of cells occurred in response, resulting in hyperplasia and acanthosis of the skin [26]. 
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Skin tissue and lung tissue appear to have different responses to the overexpression of collagenase, as 
the skin has the ability to regenerate cells which would have resulted in the hyperplastic lesions 
observed in the study [26], whereas the repair of lung cells is more restricted, and resulted in 
emphysema as a result of alveolar destruction [27]. Subsequently, MMP-1 protein, mRNA expression, 
and proteolytic activity were detected in the lung parenchyma of emphysema patients, and not in 
normal healthy patients [17], supporting the results of the animal studies and establishing MMP-1 as a 
fundamental degradative enzyme in the destructive disease of emphysema. 
MMP-13, another member of the collagenase family, was recently discovered to be increased in 
alveolar macrophages and type II pneumocytes of COPD patients [28], and its expression was also 
found to correlate with shedding and aggregation in the bone marrow in non-small cell lung cancer 
patients, the effects of which are coincide with poorer survival rates [29]. MMP-13 mRNA is increased 
due to short term smoke exposure in the muscularized small intrapulmonary arteries in mice, through 
induction of the tumor necrosis factor alpha (TNF α) pathway [30]. Cigarette smoke increases TNFα in 
vitro, through the activity of necrosis-factor kappa B (NF-κB) transcription factor [31], which is 
released by macrophages that are recruited to the lungs in response to cigarette smoke, and is therefore 
a major regulator of the protease imbalance after cigarette smoke exposure [12]. 
Proteolytic enzymes synergistically degrade the ECM and expression of one protease can then lead 
to the induction and/or activation of other proteases. MMP-13 activates proMMP-9 in vitro, which can 
result in the continued degradation of the ECM in vivo [32]. In addition, degraded collagen molecules 
denature gelatin, which is cleaved into smaller peptides by gelatinases, such as MMP-9 [33,34]. It is 
highly likely that the overall mechanism of destruction in COPD and lung cancer involves multiple 
proteases acting through intricate interactions with each other, their specific inhibitors, and their matrix 
substrates [14,35–39]. Our lab established a role for MMP-9 expression in the progression of lung 
degradation and the development of emphysema by expressing human MMP-9 in the macrophages of 
transgenic mice [40]. 
MMP-8 has also been implicated in the development of progressive lung diseases. Expression of 
MMP-8 and MMP-9 are up regulated in the induced septum of COPD patients [41], and MMP-8 
localizes with neutrophils within the alveolar septa and alveolar spaces of the lung tissue in COPD 
patients [42]. The up regulation and localization of MMP-8 in neutrophils was associated with an 
increased presence of MMP-1 in the interstitial and alveolar macrophages [42]. The increased presence 
of inflammatory cells causes oxidative stress in the lung, which in addition to the increase in 
proteolytic activity from collagenases and other metalloproteinases, likely results in the development 
of COPD, and predisposes the lung to other insults. 
2.2. Cancer and Collagenases 
These same enzymes that carry importance in emphysema, have a vital role in tumor invasion and 
metastasis [14,35–39,43]. MMPs have been studied and implicated in the development of increasingly 
aggressive cancer cells, due to the proteolytic activity of MMPs and their degradation of the structure 
of tissue barriers [14]. The degradation of the ECM is a critical step in tumor development, as it leaves 
damaged surrounding tissue that can be used as a scaffold for migration for metastatic tumor  
cells [44,45]. Studies have shown that high levels of MMP-9 are associated with poorly differentiated 
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non-small cell lung cancer [36]. Another study provided evidence that low levels of MMP-9, both  
in vivo and in vitro, allowed for increased tumor angiogenesis; the vascularization of tumor cells is 
essential for tumor growth [37]. This same study also revealed that high levels of MMP-9 in vivo 
exhibit an anti-tumorigenic effect by producing angiostatin, an inhibitor of angiogenesis [37]. Tumor 
associated macrophages (TAM) also release MMP-9, and the increase in MMP-9 can result in the 
release of matrix-sequestered vascular endothelial growth factor-A (VEGF-A) [39,46]. Studies have 
shown that VEGF receptor (VEGFR) positive distal organs are more likely to become metastatic sites 
for cancer cells [39,47]. 
More specifically, recent data supports the notion that an elevated presence of collagenases is 
associated with an increase in the severity of cancer. A specific MMP-1 allele, the 2G allele, is 
associated with a higher risk of lung cancer in individuals who have never smoked as well as in 
patients with the adenocarcinoma subtype of non-small lung cell cancer [38]. It is possible that the 
different derivatives of the MMP1 allele result in varying levels of transcription and expression of 
MMPs in the cellular environment, resulting in a greater susceptibility to cancer in patients with the 
2G allele. Our lab has shown that increased MMP-1 synthesis can predispose the cellular environment 
to tumor development and tumor aggressiveness, in addition to its central role in emphysema [26]. 
Patients with COPD are likely more predisposed to lung cancer, due to the increased presence of 
MMPs and MMP promoter activity caused by the presence of cigarette smoke elements [19,38] The 
consistent interaction of MMPs with the cell surface allows proteinases to specifically target points 
where tumor cells are in contact with the ECM, which can improve the survival and migration 
potential of tumor cells [14]. MMP-1 interacts with the tumor cell surface through an extracellular 
matrix metalloproteinase inducer (EMMPRIN), suggesting that the binding and activation of MMP-1 
by EMMPRIN may be a significant step in the development of aggressive tumor cells [14,44,48]. It 
has also been shown that the up-regulation of membrane-type 1 matrix metalloproteinase (MT1-MMP) 
cleaves and activates EMMPRIN, further supporting the notion that the activation of one specific 
MMP can result in the release of others [45]. 
The degradation of the ECM surrounding tumor cells is an intricate, complex process that likely 
involves multiple proteinases during tumor development. In addition to MMP-1, studies have 
identified MMP-13 as a collagenase that is associated with a high risk of lung cancer [29,33,49–51]. 
MMP-13 is critical for angiogenesis in wound tissue in mice [51], suggesting that an increased 
presence of MMP-13 leads to greater vascularization. In addition to this data, an increase in the 
presence of MMP-13 is associated with malignant tumors, and the transformation of benign tumors to 
malignant [50]. A possible explanation is that tumor cells stimulate the production of MMP-13 in 
adjacent cells, as high levels of MMP-13 mRNA were observed in stromal cells adjacent to MCF-7 
breast cancer cells in vitro [52]. Induction of MMP13 production by breast cancer cells has also been 
shown to facilitate metastasis [45,53]. 
MMPs also degrade the ECM in a fashion that allows tumor cells to be released from binding 
factors in their environment, and increase the motility of the cells [14]. MMPs appear to predispose the 
sites to cancer, in part by providing areas for endothelial cells to migrate and form new fixtures for 
blood vessels, and by also releasing a variety of ECM sequestered signaling factors from the cell 
surface [14], which may stimulate growth pathways of the cell resulting increased cell proliferation [26]. 
The expression of MMP-13 has been associated with the presence of tumor cells in the bone marrow of 
Cancers 2015, 7 334 
 
non-small lung cancer patients, and a reduced prognosis compared to MMP-13 negative patients [29]. 
Although bone marrow micro-involvement is not fully associated with the likelihood of tumor 
metastasis [54], it is a strong indicator of tumor progression and of a worsening prognosis [29]. In 
addition, data correlates the presence of collagenases and their transcripts with a poorer prognosis of 
cancer [3,5,14,50,55]. 
MT1-MMP has been shown to induce the epithelial-mesenchymal transition (EMT) in several 
carcinomas [45]. EMT is an indicator of tumor progression and the development of metastasis, and is  
a process by which cells transition from an epithelial to a mesenchymal phenotype [3], and is  
essential for tumors to develop motility and invasive characteristics [56]. EMT is significant in  
both lung cancer and COPD progression due to the significance of cell migration in the progression of  
both diseases [3,56,57]. MMPs can degrade E-cadherin and release cytokines and transcription factors 
that reduce the E-cadherin expression, and consequently induce EMT [56]. A recent study shows a 
correlation between MMP-1 expression and circulating breast cancer tumor cells and a relationship 
between MMP-1 expression and high tumor cell proliferation [55]. Further studies on MMP-1 
involvement in EMT may reveal and important mechanistic step in the development of tumor cells 
metastatic potential. 
3. Cigarette Smoke in COPD, Lung Cancer through the Regulation of Collagenase  
Epidemiological studies suggest a connection between the development of COPD and lung cancer 
in addition to the role of environmental smoke exposure in the development of both diseases [3]. There 
is a known positive correlation with a previous diagnosis of COPD, emphysema, and the development 
of lung cancer [58], with further studies showing that the presence of emphysema is associated with a 
lower likelihood of survival in lung cancer patients [5]. Cigarette smoke leads to alters gene expression 
within the epithelial cells of the lung leading to lung damage and aberrant lung function [10,59,60]. 
Joos and colleagues showed that the expression of specific MMP-1 alleles was associated with faster 
decline in lung function in smokers developing emphysema [61]. Furthermore, it is known that 
reduced pulmonary function then increases the risk of both COPD and lung cancer [3]. Collagenases 
can alter lung function in both COPD and lung cancer by destroying the alveolar wall structure and 
releasing cytokine and growth factors that could stimulate tumor growth [56]. MMP-1 alleles have also 
been associated with the presence and increasing severity of different cancer lines [61–64]. 
It is known that there is an increase in the expression of interstitial collagenase in patients with 
emphysema [65]. This can be attributed to the physical damage of the lung caused by the cigarette 
smoke, which not only increases proteases within the lung parenchyma, but also results in the 
recruitment of immune cells that produce MMPs [12,31]. 
It is likely that the augmentation and prolonged presence of MMPs could result in the modification 
of mechanisms in the lung that results in the development of tumors and COPD. The continued 
degradation of the ECM releases cytokines and chemokines from the ECM. The epithelial cytokine, 
CXCL14, is up regulated in vitro by the presence of CSE, and in vivo in patients with smoke induced 
COPD, and further elevated in patients with non-small cell lung cancer [66]. The most elevated levels 
of CXCL14 were observed in areas in which lung cells had undergone EMT [66]. EMT is both 
observed in COPD and lung cancer, and the increased presence of MMPs may be a result of the 
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degradation of E-Cadherin; the soluble form of E-Cadherin that is then released further stimulates and 
increases the production and release of MMPs [67]. 
4. Limitations of Collagenase Research 
One current restriction with research on MMPs is the lack of animal models that naturally produce 
murine MMP-1 with homologous functionality to human MMP-1. MMP13 is the main natural collagenase 
studied in rodent models. Although mouse orthologues of MMP-8 and MMP-13 have been identified 
and studied [68,69], mice lack expression of a MMP-1 gene that confers a protein with the same 
specificity as the human MMP-1 [70]. Murine proteinases Mcol-A (MMP-1a) and Mcol-B (MMP-1b) 
have been described as orthologues of human MMP-1 [70]. Mcol-A was found to be the most likely to 
have homologous functions to human MMP-1 [70]. However, our lab has recently shown that these 
novel proteinases did not respond to cigarette-smoke extract (CSE) in vitro [71], unlike human MMP-1 
which is significantly up regulated by CSE, thus reducing the possibility of using the expression of 
MMP-1a or MMP-1b in cigarette smoke models. The varying responses to CSE may be due to the 
differences in the distal 1 kb promoter region observed by our lab (Carver et al. under revision) [19]. 
Further research needs to be completed to find a natural homologue to human MMP-1 in murine 
models of cigarette smoke. 
Research on the collagenases has focused on the digestion of ECM substrates, such as collagen. 
Collagenases also have important non-ECM substrates. MMP-1 and MMP-13 non-ECM substrates 
include α1-antichymotrypsins and CTGF; MMP1 specific non-ECM substrates include α2-M, α1-P1, 
IGFBP-2,3,5, and proIL-1β; MMP-13 specific substrates include pro-TGF-β, and MMP-8 specific 
non-ECM substrates include α1-PI [13]. Potentially, the collagenases act through non-ECM 
mechanisms that have an effect on the development of COPD and lung cancer. In addition, MMP-1 
directly activates protease-activated receptors (PAR) on the breast cancer cell surface, which results in 
pro-invasive signals [72]. Tumor-derived MMP-1 has also been shown to activate PAR, resulting in 
acute endothelial cell activation, and pro inflammatory signals [73]. The physiological changes that 
occur can increase the metastatic potential of tumor cells, thus providing an alternative mechanism 
where collagenases influence the progression of cancer cells. 
Due to the pro-inflammatory and pro-carcinogenic signals MMPs modulate, research has focused 
on the development of synthetic MMP inhibitors (MMPi) as therapeutic drugs that could prevent ECM 
degradation, thus inhibit the development of COPD and cancer. However, clinical trials using MMPi 
for cancer treatment have generally not provided positive results, some even resulting in a poorer 
survival rate [14]. One possible issue with current synthetic inhibitors is the fact that they do not target 
a specific, individual MMP, but cover a broad number of family members. Research has now shown 
that MMPs, as regulators of cytokine and growth factor availability, have a wide and complex set of 
roles that can also be protective in certain cancers, instead of protumorigenic [74]. Thus, non-specific 
inhibition of MMPs can lead to a poorer prognosis. Development of an MMPi that is selective for a 
specific collagenase is still a potential approach to treat cancer patients [14]. Advances in technology 
allow for the development of new synthetic MMPi’s that specifically target single MMP family 
members are most relevant in the respective line of cancer research [74]. 
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5. Future Directions 
The expression of collagenases is vital in the pathogenesis of both lung cancer and COPD, and the 
development of better animal models is critical for future advances in research. It is important to create 
a more reliable transgenic mouse model to be utilized for cigarette smoke studies that will effectively 
document the induction of collagenase within the lung parenchyma by cigarette smoke in order to 
better understand the downstream effects of this induction. 
Clinically, collagenases can still serve as potential therapeutic targets for progressive chronic lung 
diseases. MMP-1 and MMP-13 should continue to be looked upon as targets in cancer and COPD 
therapy. Highly selective inhibitors of MMP-1 and MMP-13 could down regulate the expression of 
these collagenases, decreasing the activation and release of other signaling factors and proteinases, 
thus resulting in a more successful therapy. Naturally derived MMPi could also be isolated and utilized 
to target MMP-1 and MMP-13, which may reduce the likelihood of unwanted interactions and 
improve results. Most importantly, factors upstream of MMP-1 and MMP-13 regulation can serve as 
potential targets of inhibition and result in a better prognosis without interrupting vital pathways the 
cell requires for healthy ECM interaction. One such target would be the TLR-4 signaling pathway. We 
have shown TLR-4 regulates the expression of MMP-1 upon cigarette smoke; furthermore, the lungs 
from smokers exhibit elevated levels of TLR-4 and MMP-1 [20]. Additional regulators of the TLR-4 
smoke signaling pathway may unveil new therapeutic targets that can be inhibited to down regulate the 
expression of MMPs in the presence of cigarette smoke, which would likely be beneficial in the 
treatment of both COPD and lung cancer. 
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